. Author manuscript; available in PMC: 2017 Mar 5.

Published in final edited form as: Breast Cancer Res Treat. 2016 Mar 5;156(1):183–194. doi: 10.1007/s10549-016-3724-0

Table 1.

Distribution of clinical characteristics among the 1308 participants with any information on methylation (gene-specific and/ or global) and body mass index in a population-based cohort of women diagnosed with first primary breast cancer, Long Island Breast Cancer Study Project

Covariate	N (%)
Age at diagnosis
<50 years	373 (28.5)
≥50 years	935 (71.5)
Menopausal status
Premenopausal	401 (31.3)
Postmenopausal	880 (68.7)
Family history of breast cancer
No	1025 (80.8)
Yes	243 (19.2)
Body mass index (BMI)
BMI < 25 kg/m²	584 (44.7)
BMI 25–29.9 kg/m²	423 (32.3)
BMI ≥ 30 kg/m²	301 (23.0)
Cancer type
In situ	203 (15.5)
Invasive	1105 (84.5)
Estrogen receptor status
Positive	653 (74.5)
Negative	223 (25.5)
Progesterone receptor status
Positive	564 (64.4)
Negative	312 (35.6)
Tumor size
<2 cm	473 (65.9)
≥2 cm	245 (34.1)
Nodal involvement
0	548 (75.9)
1	174 (24.1)
Treatment type
No chemotherapy	538 (60.1)
Chemotherapy	357 (39.9)
No radiation	356 (39.6)
Radiation	542 (60.4)
No hormone therapy	335 (38.0)
Hormone therapy	547 (62.0)